Stage II Oropharyngeal Squamous Cell Carcinoma
7
0
0
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
28.6%
2 terminated out of 7 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
120%
6 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery
Ganetespib Window of Opportunity Study in Head and Neck Cancers